Back to Journals » Journal of Blood Medicine » Volume 17 Authors Kim DDH, Busque L, Hillis C, Laneuville P, Savoie ML Received 26 May 2026 Accepted for publication 5 September 2026 Published 23 September 2026 Volume 2026:17 627651 DOI https://doi.org/10.2147/JBM.S627651 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 2 Editor who approved publication: Professor Safaa A A Khaled Dennis Dong Hwan Kim,1 Lambert Busque,2,3 Christopher Hillis,4 Pierre...
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Lambert Busque
Symptom burden in myeloproliferative neoplasms: clinical correlates, dynamics, and survival impact-a study of 784 patients from the Quebec MPN research group | Blood Cancer Journal
Classic BCR::ABL1-negative myeloproliferative neoplasms (MPN) include polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofibrosis (PMF). While patients may benefit from extended survival, they also endure lifelong symptoms, ranging from mild to incapacitating [1].
Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study - Blood Cancer Journal
Dear Editor Tyrosine kinase inhibitors (TKI) targeting the BCR::ABL1 fusion gene have dramatically improved the prognosis of patients with chronic myeloid leukemia (CML) to the point where most patients can enjoy a normal life expectancy [1]. Outside of clinical trials, the use of different TKIs in 1 L is largely influenced by drug accessibility, toxicity profile [2], and treatment-free remission (TFR) as the therapeutic goal [3].
Fibrosis and treatment‐free remission in chronic myeloid leukaemia
DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request.
Improved identification of clinically relevant Acute Leukemia subtypes using standardized EuroFlow panels versus non‐standardized approach
1 INTRODUCTION Flow cytometry plays an integral role in the diagnostic work-up and classification of acute leukemias (ALs) as described in the World Health Organization (WHO) classification (Arber et al., 2016; Khoury et al., 2022).
Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study
1 INTRODUCTION Chronic myeloid leukemia (CML) patients in chronic phase (CP) now enjoy a normal life expectancy thanks to the routine use of tyrosine kinase inhibitors (TKIs).1, 2 These drugs are able to induce not only a complete cytogenetic response (CCyR) in over 80% of subjects,3 but also a deep molecular response (DMR or MR4), defined as BCR::ABL1 transcript levels ≤0.01% according to the International Scale (IS), in more than 50% of patients.4, 5 The possibility of treatment...
“Perioperative management of myeloproliferative neoplasms: a pan‐Canadian physician survey and international expert opinion”
CORRESPONDENCE This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/ajh.26739.
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms - Leukemia
|
By Joseph Khoury, Eric Solary, Yassmine Akkari, Jane F. Apperley, Rafael Bejar, Lambert Busque, Weina Chen, John Choi, Isabel Colmenero, Jean-François Emile, Torsten Haferlach, Shimin Hu, Rashmi Kanagal-Shamanna, Hagop Kantarjian, Christian P. Kratz, Sanam Loghavi, Kikkeri N. Naresh, Yasodha Natkunam, Eric Padron, Nikhil V. Patkar, Uwe Platzbecker, Anna Schuh, Prashant Tembhare, Jeffrey W. Tyner, Srdan Verstovsek, Wei Qing Wang, Wenbin Xiao, Andreas Hochhaus Verified, Emiko Takahashi
|
Nature
Verified
Abstract The upcoming 5th edition of the World Health Organization (WHO) Classification of Haematolymphoid Tumours is part of an effort to hierarchically catalogue human cancers arising in various organ systems within a single relational database. This paper summarizes the new WHO classification scheme for myeloid and histiocytic/dendritic neoplasms and provides an overview of the principles and rationale underpinning changes from the prior edition.
Novel germline mutations in the calreticulin gene: implications for the diagnosis of myeloproliferative neoplasms
Mutations in the calreticulin (CALR) gene are found in the majority of Janus kinase 2-negative myeloproliferative neoplasms MPN and, thus far, have exclusively been reported as acquired, somatic mutations. We assessed the mutational status of exon 9 of the CALR gene in 2000 blood samples submitted to our centre and identified 12 subjects (0.6%) harbouring distinctive CALR mutations, all with an allelic frequency of 50% and all involving indels occurring as multiples of 3 bp.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Lambert
Contact Lambert, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack